Johnson & Johnson has agreed to acquire Proteologix to expand its dermatology portfolio for an aggregate of $850M in cash
The acquisition adds Proteologix’s PX128, which will be entering P-I clinical evaluation to treat severe atopic dermatitis (AD) & moderate to severe asthma as well as PX130, currently under preclinical evaluation for moderate to severe AD, along with additional bispecific antibody programs for a range of diseases to J&J’s portfolio
PX128 works by inhibiting IL-13-mediated Th2 skin inflammation and TSLP-mediated tissue inflammation while PX130 targets IL-13 similar to PX128 and IL-22, enabling restoration of skin barrier & preventing inflammation from allergens for treating AD & asthma
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
